Dr.Gregory K. Bell is quoted in this article published by BioPharm International about the regulatory and legal issues associated with bringing recent biosimilars and biobetters to market. Click below to read the article.
Consequences of counterfeit pharmaceutical product sales
Recently, both the FDA and EMA have raised concerns about counterfeit drug products, including GLP-1s used for weight loss and diabetes, being marketed in the...